PRINCETON, NJ - May 16, 2019 - Certara® the global leader in model-informed drug development, regulatory science, real-world evidence and market access services, announced today that it has appointed Dr. William F. Feehery as its new Chief Executive Officer (CEO) and a member of the Certara Board of Directors, effective June 3, 2019.
Dr. Feehery joins Certara from DuPont, where he has served since 2013 as president of DuPont Industrial Biosciences, a $2.2 billion global biotechnology business which experienced significant growth and profitability under his leadership. In that role, he had full P&L responsibility for 3,000 people, including 500 R&D staff, 20 manufacturing plants, and worldwide marketing and sales across multiple markets. He joined DuPont in 2002 and has prior experience in venture capital and as a consultant for the Boston Consulting Group. Dr. Feehery also serves as a board member for West Pharmaceutical Services (NYSE: WST), a manufacturer of packing components and delivery systems for pharmaceutical, biotech and medical device companies.
Dr. Edmundo Muniz, who has served as Certara CEO since June 2014, will become a member of the Certara Board of Directors and Chair of the Boards newly-formed Science Committee. During Dr. Muniz tenure as CEO, Certara has grown to become the world leader in model-informed decision support solutions for drug development, regulatory science and market/patient access.
We are very pleased to welcome Bill to Certara. Bills broad and diverse background in technology and commercial operations position him well to lead the company. We are confident that his technical, operational and commercial expertise will serve him well as he takes the company to its next level of growth, said Sheri McCoy, Certara Chairman of the Board. She went on to say that we also want to thank Edmundo for the great work he has done in establishing the vision and strategy that has resulted in Certara becoming the world leader in model-informed drug development and a critical innovator in modeling and simulation.
I am excited to join Certara, an exceptional company that is reducing the cost, time, and risk of drug development. I could not have made a better choice than to join the company at this exciting time in its growth trajectory, said Dr. Feehery. Certaras track record for optimizing drug development and patient care decision-making by leveraging its integrated portfolio of quantitative and
in silico
capabilities is impeccable. The company has already had a significant positive impact, helping to bring safer and more effective new therapies to market efficiently. The healthcare field is ripe for accelerated innovation of this type and Certara is poised to lead the market.
Dr. Feehery holds both a PhD in chemical engineering and an MBA from MIT. He was a Churchill Scholar at Cambridge University, and received his BSE in chemical engineering from the University of Pennsylvania. His doctorate, awarded while he was the recipient of a National Science Foundation Fellowship, involved developing software and mathematical methods for modeling complex systems.
About Certara
Certara enables superior drug development and patient care decision-making through model-informed drug development, regulatory science, real-world evidence solutions and knowledge integration. As a result, it optimizes R&D productivity, commercial value and patient outcomes. Its clients include hundreds of global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 60 countries. For more information, visit
www.certara.com
.